Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
46 Cards in this Set
- Front
- Back
Type 1 DM |
Autoimmune destruction of the beta cells of the pancreas
|
|
Type 2 DM
|
Combination of insulin resistance and relative insulin deficiency; progressively lower insulin secretion over time
|
|
Risk factors for Type 2 DM
|
1st degree relative w/ DMNative American, African American, Asian, Hispanic, Pacific IslanderOverweightPhysical inactivityHTNHDL < 35 and/or TG > 250Hx of CVFPolycystic ovarian syndrome
|
|
Microvascular complications
|
RetinopathyNephropathyPeripheral neuropathyAutonomic neuropathy (ED, gastroparesis, loss of bladder control)
|
|
Macrovascular complications
|
Coronary artery disease (HTN, MI, HF)Cerebrovascular disease (TIA/stroke)Peripheral artery disease
|
|
DM lifestyle modifications
|
Weight lossWaist circumference < 35 in (female), < 40 in (male)DietMonitor carb intakeLimit saturated fat intake < 7% of total caloriesMinimize trans fat intakeExercise 30 min x 5 daysSmoking cessation
|
|
Vaccinations required for diabetics
|
InfluenzaHep BPneumovaxTdaP
|
|
Metformin
|
GlucophageBiguanideIR 500 mg QD-BID or 850 mg QDER 500-1000 mg QD w/ dinner1st line therapy for DMBLACK BOX --- lactic acidosis
|
|
Janumet
|
Sitagliptin + Metformin
|
|
Metformin Contraindications
|
SCr > 1.4 (female) or > 1.5 (male)CrCl < 60 mL/minMetabolic acidosisTemporary d/c w/ iodinated contrast media (resume after 48 hrs if renal function is normal)STOP in any case of hypoxiaHepatic impairment
|
|
Metformin Adverse Effects
|
D/N/V/flatulenceWeight neutral
|
|
Metformin Interactions
|
Alcohol, iodinated contrast dye - increase risk of lactic acidosisDecreases Vitamin B12 absorption
|
|
Glipizide
|
GlucotrolSulfonylureaIR 5-10 mg BIDXL 5-10 mg QD, max 20 mg QD
|
|
Glimepiride
|
AmarylSulfonylurea1-2 mg QD, max 8 mg QD
|
|
Glyburide
|
DiaBeta2.5-5 mg QD, max 20 mg/dContraindicated in CrCl < 50 ml/min
|
|
Metformin MOA
|
Decreases hepatic glucose productionDecreases intestinal absorption of glucoseImproves insulin sensitivity
|
|
Sulfonylurea Info
|
Stimulate insulin secretion from the pancreatic beta cellsSE - hypoglycemia, weight gainCYP 2C9 substratesTake w/ food
|
|
Sulfonylurea Contraindications
|
Use w/ meglitinidesSulfa allergyGlyburide --- CrCl < 50 mL/min
|
|
Meglitinide Info
|
Stimulate insulin secretion from the pancreatic beta cellsSE - hypoglycemia, mild weight gain, upper respiratory tract infxnRepaglinide, nateglinide
|
|
Pioglitazone
|
Actos15-30 mg QD, max 45 mg QDContra in active bladder cancer
|
|
Thiazolidinedione MOA
|
Peroxisome proliferator-activated receptor gamma agonistsIncreases uptake and utilization of glucose by the peripheral tissues
|
|
TZD Warnings and Side Effects
|
BLACK BOX --- NYHA Class III/IV heart failureDon't use pioglitazone in active bladder cancerCYP 2C8 substratesSE - peripheral edema, weight gain, UTRIsCHF, increased fracture risk, increased LFTs
|
|
Alpha Glucosidase Inhibitors
|
Cause reversible inhibition of membrane-bound intestinal alpha-glucosidases which hydrolyze oligosaccharides and disaccharides to glucoseDelays glucose absorptionEx. Acarbose, Miglitol
|
|
Alpha-Glucosidase Inhibitor Warnings and Side Effects
|
Contra in inflammatory bowel disease, colonic ulceration, partial or complete intestinal obstructionSE - GI effects, weight neutralTake w/ full glass of water w/ 1st bite of foodTreat hypoglycemia w/ glucose tablets or gel
|
|
Sitagliptin
|
JanuviaDPP-4 Inhibitor100 mg QDCrCl 30-49 --- 50 mg QDCrCl < 30 --- 25 mg QD
|
|
DPP-4 Inhibitors
|
Prevent the enzyme DPP-4 from breaking down incretin hormones, GLP-1, and GIPIncrease insulin release from the pancreatic beta cellsDecrease glucagon secretion from pancreatic alpha cellsEx. Sitagliptin, saxagliptin, linagliptin (no renal dose adjustment), alogliptin
|
|
DPP-4 Inhibitor Adverse Effects and Interactions
|
Nasopharyngitis, Upper RTIs, UTIs, peripheral edema, rash, hypoglycemiaWeight neutralSaxagliptin --- CYP 3A4 substrateLinagliptin --- CYP 3A4 and P-glycoprotein substrate
|
|
Canagliflozin
|
InvokanaSGLT2 Inhibitor100 mg Qbreakfast (max 300 mg Qbreakfast)CrCl 45-60 - 100 mg maxContra in CrCl < 45 mL/min
|
|
SGLT2 Inhibitors
|
Reduces reabsoprtion of filtered glucose and lowers renal threshold for glucose --- increases urinary glucose excretionUGT substrateEx. Canagliflozin
|
|
SGLT2 Inhibitor Side Effects and Misc.
|
SE - female genital mycotic infxns, UTIs, hyperkalemia, increased urination, hypoglycemiaContra - CrCl < 30 mL/min, ESRD, or on dialysisIncreases AUC of digoxin
|
|
Exenatide
|
Byetta, Bydureon (ER)GLP-1 agonistIR --- 5 mcg SC BID x 1 month, then 10 mcg SC BIDER --- 2 mg SC q7 days
|
|
GLP-1 Agonists MOA
|
Analogs of glucagon-like peptide-1Increases insulin secretionDecreases glucagon secretionSlows gastric emptying and improves satietyEx. Exenatide, liraglutide
|
|
GLP-1 Agonists Misc.
|
BLACK BOX --- possible thyroid cancerContra - family hx of medullatry thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, CrCl < 30 mL/min, severe GI diseaseSE - nausea, V/D/C, weight loss, hypoglycemiaPancreatitis, caution in moderate renal impairment
|
|
Liraglutide
|
VictozaGLP-1 Agonist0.6 mg SQ QD x 1 wk, then 1.2 mg SQ QD
|
|
Pramlintide
|
SymlinAnalog of amylinSlows gastric emptying and increases satietySE --- hypoglycemia, nausea, anorexiaBLACK BOX - coadmin w/ insulin
|
|
Bromocriptine
|
CyclosetDopamine agonistWorks in the CNS to decrease insulin resistanceTake w/ food
|
|
Rapid acting Insulin
|
Aspart (Novolog), Glulisine (Apidra), Lispro (Humalog)Last for a mealDosed for amount of carbs in a meal or in fixed regimenClear
|
|
Regular insulin
|
Humulin R, Novolin RInject 30 min before mealOnset of action - 30 minutes, lasts 6-10 hoursClear
|
|
NPH insulin (Intermediate insulin)
|
Humulin N, Novolin NOnset is 1-2 hours, peak of 4-8 hours, duration of 24 hrsCloudy
|
|
Long-acting insulin
|
Detemir (Levemir), Glargine (Lantus)Onset 1-2 hrs, duration ~24 hrsDO NOT PEAKDon 't mix w/ other insulins
|
|
Diabetes drugs that cause hypoglycemia
|
InsulinSulfonylureas and meglitinidesGLP-1 agonist, DPP-4 inhibitor, TZDs, InvokanaPramlintide (Symlin)
|
|
Symptoms of hypoglycemia
|
Dizziness, HAAnxiety, shakinessSweating, excessive hungerConfusion, clumsy or jerky movementsTremors, palpitations, blurred vision
|
|
Diabetic ketoacidosis (DKA)
|
Occurs when there is not enough insulin and the body breaks down fat to make energyMay be initial presentation of Type 1 DM or the result of patient stopping insulin therapy
|
|
DKA Symptoms
|
HyperglycemiaPolyuria, polyphagia, polydipsiaBlurred visionMetabolic acidosis (fruity breath, dyspnea)Dehydration
|
|
DKA Lab Values
|
Glucose > 300Ketones (+) in urine and bloodpH < 7.2Bicarb < 15WBC 15-40
|
|
DKA Treatment
|
IV fluids, electrolytesInsulin
|